{"slug":"novo-nordisk-accelerates-clinical-documentation-and-drug-development-with-claude","url":"https://findausecase.com/use-cases/novo-nordisk-accelerates-clinical-documentation-and-drug-development-with-claude","title":"Novo Nordisk accelerates clinical documentation and drug development with Claude","description":"Novo Nordisk, a global pharmaceutical company headquartered in Europe, built NovoScribe, an AI-powered documentation platform using Claude Code, Amazon Bedrock and MongoDB Atlas, to automate clinical study report (CSR) generation. Claude helped cut writing times on CSRs by 90%, reducing time spent producing clinical study documentation from 10+ weeks to 10 minutes, and delivered a 95% reduction in resources needed to create device verification protocols. The platform expanded from clinical trial reports to device protocol documentation and patient materials, and an 11-person development team, including non-technical staff, now prototypes features using Claude Code.","company":"Novo Nordisk","industry":"Life Sciences","aiCapabilities":["Generative AI","Document Intelligence"],"technology":["Claude Code","Amazon Bedrock","MongoDB Atlas"],"deployment":"Public Cloud","problemStatement":"For pharmaceutical companies, the path from drug discovery to patient access is paved with paperwork. Producing the documentation for a clinical trial consumed so much time and so many resources, even with help from external agencies, that it was slowing down the organization's ability to bring new medicines to market. Staff writers averaged only 2.3 CSRs per year, and the manual process remained prone to errors and subjective interpretation.","solutionApproach":"Novo Nordisk used Claude Code to develop NovoScribe, a generative AI documentation platform built on Amazon Bedrock and MongoDB Atlas, with Claude models as the frontier intelligence driving the entire system. The platform combines retrieval-augmented generation (RAG) with domain expert-approved text and case-specific variables to produce accurate, compliant documentation. Initially the team focused on perfecting NovoScribe for clinical study report (CSR) production, then expanded to device protocol documentation and patient materials.","businessValue":"Claude has helped Novo Nordisk cut writing times on clinical study reports (CSRs) by 90%. Time spent producing clinical study documentation was reduced from 10+ weeks to 10 minutes, and device verification protocols saw a 95% reduction in resources needed. For new trials, the team can now produce a complete study booklet and patient guide in under a minute.","evidence":{"band":"high"},"sourceUrl":"https://claude.com/customers/novo-nordisk","dates":{"publishedAt":"2026-08-28T09:03:39.429Z","publishedAtSource":"pipeline","updatedAt":"2026-08-28T09:03:39.429Z"},"license":"Open for reading and citing with a link to https://findausecase.com/use-cases/novo-nordisk-accelerates-clinical-documentation-and-drug-development-with-claude. Bulk republication requires permission."}